Mobilizing antitumour immunity through vaccination potentially constitutes a powerful
anticancer strategy but has not yet provided robust clinical benefits in large patient …

Background Gastrointestinal (GI) cancers are the most common human tumors encountered
worldwide. The majority of GI cancers are unresectable at the time of diagnosis, and in the …

Dendritic cells (DCs)‐based vaccines are an approved method for inducing potent antigen‐
specific immune responses to eliminate tumor cells. However, this promising strategy still …

Whether vaccines are designed to prepare the immune system for the encounter with a
pathogen or with cancer, certain common challenges need to be faced, such as what …

Cancer is a chronic disease, and it can be lethal due to limited therapeutic options. The
conventional treatment options for cancer have numerous challenges, such as a low blood …

Purpose: Whole tumor lysates are promising antigen sources for dendritic cell (DC) therapy
as they contain many relevant immunogenic epitopes to help prevent tumor escape. Two …

Most studies of cancer stem cells (CSC) involve the inoculation of cells from human tumors
into immunosuppressed mice, preventing an assessment on the immunologic interactions …

We have developed a tumor vaccine in which patient-derived myeloma cells are chemically
fused with autologous dendritic cells (DCs) such that a broad spectrum of myeloma …

Dendritic cells (DCs) are potent antigen-presenting cells that have the ability to stimulate
primary T cell antitumor immune responses in animals and humans. Since the first published …

With the approval of the first therapeutic cancer vaccine by US Food and Drug
Administration, numerous therapeutic cancer vaccines have been under clinical trials with …